Related Experiment Video
Updated: Sep 28, 2025
08:36
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
747
Riboflavin for COVID-19 Adjuvant Treatment in Patients With Mental Health Disorders: Observational Study
R A Akasov1,2, E V Khaydukov1,2, D S Andreyuk3,4
1Federal Scientific Research Center Crystallography and Photonics Russian Academy of Sciences, Moscow, Russia.
Frontiers in Pharmacology
|April 1, 2022
Summary
Riboflavin (vitamin B2) supplementation, specifically flavin mononucleotide, showed promise in normalizing immune markers like neutrophil and lymphocyte counts in COVID-19 patients. This suggests riboflavin may help reduce inflammation associated with the disease.
Area of Science:
- Clinical Medicine
- Immunology
- Nutritional Science
Background:
- Drug repurposing is a vital strategy for rapid COVID-19 treatment development.
- Well-established and safe substances offer a promising avenue for therapeutic intervention.
- Mental health disorder patients present unique challenges in COVID-19 management.
Purpose of the Study:
- To investigate the effect of riboflavin (vitamin B2) supplementation on immune markers in COVID-19 patients.
- To assess the correlation between immune markers and disease severity in COVID-19 patients with mental health disorders.
- To compare inflammation levels in COVID-19 patients with organic disorders versus schizophrenia.
Main Methods:
- Observational clinical study design.
- Administration of 10 mg flavin mononucleotide (soluble riboflavin) intramuscularly twice daily for 7 days.
- Analysis of neutrophil and lymphocyte counts, their ratio, and total leucocytes.
Main Results:
- Flavin mononucleotide supplementation correlated with normalized neutrophil and lymphocyte counts and ratios.
- Neutrophil-to-leucocyte ratio (NLR) and leucocyte counts correlated with COVID-19 severity.
- Patients with organic disorders exhibited higher inflammation than those with schizophrenia.
Conclusions:
- Riboflavin supplementation may be a promising adjunctive therapy for reducing inflammation in COVID-19.
- Further clinical evaluation of riboflavin for COVID-19 treatment is warranted.
- Immune marker profiles differ between COVID-19 patients with organic disorders and schizophrenia.
Related Concept Videos
01:30Bipolar Disorder
157
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
157
01:26Psychosis: Goals of Pharmacotherapy
225
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
225
01:16Clinical Trials
9.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
9.4K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
01:22Alzheimer's Disease: Treatment
274
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
274
01:17Drugs for Treatment of Diarrhea-Predominant IBS
335
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
335